Secondary Hypertension Flashcards
Definition of Secondary Hypertension
sustained elevation of systolic and diastolic blood pressure > 140/90 mmHg
Causes of Secondary Hypertension
primary (idiopathic/essential)
No identifiable cause
secondary to:
renal disease (salt/H2O imbalance)
adrenal tumours (aldosterone)
Can be a source of hormones that induce vasoconstriction
aortic coarctation (narrowing of aorta)
Steroids, Rx
Determinants
Around 90 of hypertension is due to primary hypertension. SO < 10% of cases with high blood pressure are secondary causes.
These are underlying diseases that we can identify and hopefully cure, by removing the underlying cause:
Renal diseases (e.g. Glomerulonephritis, diabetic nephropathy)
Vascular causes (e.g. Renal artery stenosis)
Hormonal abnormalities (e.g. Conn’s syndrome, Cushing’s syndrome, Pheochromocytoma)
Drugs (Contraceptive pill; liquorice)
Pregnancy (Pre-eclampsia)
Genetic disorders
Glomerulonephritis- renal disease
It essentially is Inflammation of glomeruli
There is acute infectioin. But can also have chronic infection – some autoimmune disease can induce this inflammatory disease.
The gross features:
It is a contracted granular type of pathology of the kidney
The kidney is shrunk in size, but also has a granular morphology due to cortical atrophy of the kidney.
There will be disease mechanisms that induce this atrophy
Ultimately this will cause fluid balance issues
There will be swelling in the lower limbs
This is due to infection and inflammation of the glomeruli within the kidney.
Endocrine Hypertension (adrenal cortex)
Within the adrenal cortex there can be:
Adrenal adenoma producing aldosterone (Conn’s syndrome)
Mostly benign tumours.
Can increase blood pressure
Adrenal hyperplasia
Another type of benign
Cushing’s syndrome
This is due to a pituitary adenoma
Excess cortisol increasing adrenalin’s vasoconstrictive effect
Endocrine Hypertension (adrenal medulla)
Adrenal medulla
Pheochromocytoma (adrenalin secreting tumour)
This is another benign tumour, but because they secrete these hormones they can have adverse effects in inducing secondary hypertension.
So these tumours can be removed and ultimately cure these patients of seconcary hypertension.
Drug-induce hypertension
NSAIDs
Oral contraceptives
Alcohol
Cocaine
Cyclosporin, tarcolimus (immunosuppressive)
Erythropoietin – can increase BP level by balance of vasodilators and vasoconstrictors
Glucocorticoids
Liquorice (can ↓K+ levels), Carbenoxolone is the active compound
Ginseng, yohimbin
Tyramine (found in strong cheeses) and monoamine oxidase MAO inhibitors (antidepressants)
Angiogenesis inhibitors – will focus on this
VEGF family has been targeted for cancer patients, a lot of these patients have hypertension. It has informed us about the role of VEGF in regulating vascular tone in vivo.
VEGF inhibitors: Kidney cancers
There are certain types of cancer such as kidney cancer/renal cell carcinoma.
These types of tumours are highly angiogenic and metastatic tumours.
They induce new blood vessel growth. These blood vessels allow for increased nutrience and oxygen to reach the tumours. They are also a route by which tumours or cells can escape – metastatic cells can escape from the tumours by new blood vessel growth.
So induction of new blood vessels is an aggressive type of tumour, and is also a way that tumours can increase their size and how to metastasise.
There are drugs that try to inhibit blood vessel growth. These are called anti angiogenic drugs.
VEGF inhibitors: anti-angiogenic induced hypertension
Angiogenesis – is the formation of new blood vessels. It is essential for solid tumour growth and metastasis
There are mediators, cytokines and growth factors the induce new blood vessel growth, one is called VEGF.
So angiogenesis regulated by proangiogenic soluble mediators such as vascular endothelial growth factor (VEGF)
So VEGF is a proangiogenic molecule that gets secreted by the tumour, it acts on nearby capillaries causing the capillaries to grow and migrate forming new vessels around the tumour.
So a lot of VEGF secretion can be detrimental to the patient as the cancer can grow and metastasise.
Antiangiogenic drugs that block the VEGF signalling pathway prolong progression free survival in several cancers and are now in broad clinical use
Is not a cure, but extends life.
In these patients, Hypertension is the most common CVS toxicity of this therapeutic class affecting between 19%-67% of patients
This is increasing with the increasing potency of the new VEGF inhibitors.
evidence that VEGF is involved in maintaining vascular tone
When VEGF is inhibited, (LOW VEGF) we see cases of hypertension
Have seen this also in patients on anti VEGF drugs
But there is also a study in healthy patients that shows by giving a VEGF inhibitor, it causes an increase in BP -> hypertension
Conversely:
When there is HIGH VEGF
We see a dramatic decrease in blood pressure -> hypotensive effect.
VEGF receptor 2 is predominantly involved in this effect
VEGF signalling
The primary receptors for the VEGF family are:
VEGF receptor 1
VEGF receptor 2
There is also a VEGF receptor 3
These receptors sit on the endothelial cell and also have co receptors
There is also not just one ligand, there is not just one VEGF, there are different family members of these growth factors:
Most described protein: VEGFA
There is also VEGFB, VEGFC, VEGFD
They can tissue specific activity
PLGF (placental growth factor) is another family member.
The VEGF ligands will bind to the receptors and initiate new blood vessel growth via:
Angiogenesis – new blood vessel formation from pre existing vessels
And also Vasculogenesis – de novo type of blood vessel growth where you see stem cells developing into new vessels, this is in the developing embryo
There is also lymphangiogenesis, VEGFR3 is involved in the signalling for this.
What is KDR
VEGF receptor 2
Summary of VEGF signalling
VEGF (VEGF-A) is the main component binds VEGFR-1 (sometimes called FLT-1) and VEGFR-2 (sometimes called FLK-1 or KDR)
Note: VEGFR-2 has predominant role in cell signalling
So VEFG-a binds to VEGFR-2
Neuropilins (NRP1, NRP2) are VEGF co-receptors but can also signal independently
VEGF-B has restricted angiogenic activity e.g. is more expressed in the heart
VEGF-C and VEGF-D involved in vasculogenesis and lymphangiogenesis
How do we know that VEGF has an effect on BP
When you give VEGF, you have a hypotensive effect. BP drops
Can also duplicate the effect giving soluble receptor
Study in rats:
Administering VEGF-R1 induces a drop in BP
VEGF-R2 induces a drop in BP
VEGF administration induces the largest drop in BP
So this shows that if you add VEGF or its receptor you can induce a drop in BP. The mean arterial pressure will decrease
Also looked at relaxation.
If you add VEGF there is a maximal relaxation of the vessel – this shows that VEGF is involved in relaxation
If you add VEGF-R2 (KDR) – it also a significant relaxation of the vessel
And with VEGF-R1 there is also relaxation
BUT, when you add VEGF and the vessel is denuded (the endothelial cell layer has been removed) all of the relaxation inducing effects of VEGF are completely abolished.
This shows how important the endothelial cell is to this effect, as without it there is no relaxation of the vessel.
Likely mechanism by which VEGF regulates vessel tone
VEGF binds to its receptor VEGF receptor 2
The endothelial cell is required to induce the relaxation effect by inducing nitric oxide.
This is one possible mechanism by which VEGF signals to induce NO
NO then exerts its vasodilatory effect on the SMCs
When VEGF binds ot its receptor there is multiple pathways that it regulates:
Inducing NO – can increase permeability
Can also induce angiogenesis through PIP2 Ca signalling
Can also induce the PKB pathway to increase cell survival, so apoptosis is reduced in the presence of VEGF
Can also induce the Ras Raf MEK MAPK signalling pathway which will increase gene expression, transcription and cell proliferation, and can induce angiogenesis
Therefore, by blocking VEGF signalling, a lot of these processes will be switched off, so by blocking VEGF biding you:
Inhibit cell proliferation
Inhibit angiogenesis
Prevent NO induction on the SMC relaxation – will increase vascular tone